ZLAB
Zai Lab·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZLAB
Zai Lab Limited
A biotech company that develops and commercializes innovative oncology and autoimmune therapies in China and globally
Biological Technology
03/28/2013
09/20/2017
NASDAQ Stock Exchange
1,850
12-31
Depository Receipts (Ordinary Shares)
Building 1, 4/F, Jinchuang Plaza, 4560 Jinke Road, Pudong, Shanghai, PRC
Zai Lab Limited and its affiliates are committed to addressing the huge unmet medical needs in the fields of oncology, immunity, neuroscience and infectious diseases through the discovery, development and commercialization of innovative products.
Zai Lab Limited is a holding company mainly engaged in biopharmaceuticals. The company is committed to addressing unmet medical needs in oncology, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The company has a portfolio of patented drug candidates from the discovery stage to the later stages of clinical programs. These include "Zele", "OPTUNE", "Qingle", "New Zele" and "Weiweijia".
Earnings Call
Q1/2025
Estimate EPS-0.55
Actual EPS-0.04
Estimate Revenue115.86M
Actual Revenue106.49M
Zai Lab's Q1 2025 Earnings Call: Unpacking Contradictions in VYVGART Sales and FDA Approvals
May 19,2025 03:50
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.42
Actual EPS-0.04
Estimate Revenue125.02M
Actual Revenue109.98M
Zai Lab's Q2 2025: Discrepancies in VYVGART Revenue, DLL3 Strategy, and Regulatory Timelines
Aug 07,2025 10:49
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ZLAB has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.31, missing expectations. The chart below visualizes how ZLAB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZLAB has released its 2025 Q3 earnings report, with revenue of 116.09M, reflecting a YoY change of 13.52%, and net profit of -35.96M, showing a YoY change of 13.70%. The Sankey diagram below clearly presents ZLAB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
